



# CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all health benefit plans administered by CIGNA Companies including plans formerly administered by Great-West Healthcare, which is now a part of CIGNA

Effective Date ..... 5/15/2011  
Next Review Date ..... 5/15/2012  
Coverage Policy Number ..... 0070

## Subject Allergy Testing

### Table of Contents

Coverage Policy ..... 1  
General Background ..... 2  
Coding/Billing Information ..... 7  
References ..... 9  
Policy History ..... 11

### Hyperlink to Related Coverage Policies

Allergen Immunotherapy  
Complementary and Alternative Medicine

### INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. Proprietary information of CIGNA. Copyright ©2011 CIGNA

## Coverage Policy

CIGNA covers the following in vivo allergy tests as medically necessary:

- prick/puncture and/or intradermal allergy testing to diagnose suspected immunoglobulin E (IgE) mediated hypersensitivity to inhalants, foods, hymenoptera (e.g., bee venom), drugs and/or chemicals
- skin patch testing to diagnose suspected contact allergic dermatitis
- photo patch testing to diagnose suspected contact photosensitization (e.g., photoallergic contact dermatitis)
- food/food additive ingestion double-blind challenge/provocation to diagnose suspected IgE-mediated hypersensitivity if skin testing is negative or equivocal, despite a history and physical findings suggestive of hypersensitivity
- drug provocation/bronchial challenge test to diagnose suspected IgE-mediated hypersensitivity when there is a confirmed history of allergy to a drug, and the individual requires the particular drug for treatment of a diagnosed condition, and there is no effective alternative drug available
- skin serial endpoint titration for determination of a safe starting dose for testing or immunotherapy when there is potential for the specific allergen in question to produce a severe systemic reaction or anaphylaxis (such as with bee venom)

CIGNA covers in vitro allergy testing (blood serum analysis, e.g., ImmunoCAP<sup>®</sup>, radioallergosorbent test [RAST], multiple radioallergosorbent test [MAST], fluorescent allergosorbent test [FAST], paper radioimmunosorbent test [PRIST], radioimmunosorbent test [RIST], enzyme-linked immunosorbent

**assay [ELISA], MRT [modified RAST], and VAST) as medically necessary when ANY of the following criteria is met:**

- for the diagnosis of suspected IgE-mediated food or inhalant allergies for one of the following indications:
  - individuals with severe dermatographism, ichthyosis or generalized eczema
  - individuals who cannot be safely withdrawn from medications that interfere with skin testing (such as long-acting antihistamines, tricyclic antidepressants)
  - individuals who have a history of a previous systemic reaction to skin testing
  - individuals in whom skin testing was equivocal/inconclusive and in vitro testing is required as a confirmatory test
- as an alternative to skin testing for the evaluation of cross-reactivity between insect venoms
- when specific IgE immunoassays are used as adjunctive testing for disease activity of allergic bronchopulmonary aspergillosis and certain parasitic diseases

**CIGNA does not cover in vitro allergy testing for ANY of the following, because it is considered not medically necessary:**

- individuals with no contraindications to skin testing
- individuals being treated successfully for allergies
- individuals with mild symptoms
- individuals who have had negative skin testing for the allergy in question

**CIGNA does not cover the following in vivo and in vitro allergy tests in the diagnosis or management of allergic disease because they are considered experimental/investigational or unproven (this list may not be all-inclusive):**

- nasal challenge/provocation
- conjunctival challenge/provocation
- bronchial provocation/challenge testing for common allergens (e.g., dust, ragweed)
- provocation-neutralization testing (subcutaneous, sublingual or intradermal) or Rinkel test
- electrodermal testing or electro-acupuncture
- applied kinesiology or muscle strength testing of allergies
- reagenic pulse testing or pulse testing for allergies
- total serum IgE (except as noted in the General Background section of this coverage position)
- total serum immunoglobulin G (IgG), immunoglobulin A (IgA) and immunoglobulin M (IgM)
- testing of specific IgG antibody (e.g., by RAST or ELISA testing)
- cytotoxic testing, leukocytotoxic testing or Bryan's test
- lymphocyte subset counts
- lymphocyte function assay
- cytokine and cytokine receptor assay
- food immune complex assay (FICA)
- leukocyte histamine release testing
- body chemical analysis
- antigen leukocyte cellular antibody (ALCAT) automated food allergy testing

---

## **General Background**

Allergies result from an overreaction of the immune system to foreign substances. An allergy develops when the body is exposed to a substance that prompts the initiation of an immune response. This response involves the production of antibodies, called immunoglobulins (Igs), which are directed against proteins of the foreign substance, called allergens or antigens. While there are five classes of immunoglobulins, it is IgE that is typically involved in allergic reactions. When an allergy-prone individual is exposed to a specific antigen, B-cells produce

an IgE that recognizes only that antigen. This antigen-specific IgE then binds to receptors on specific cells that reside in tissue (mast cells) or circulate in the blood (basophils). Upon re-exposure to the same antigen, the antigen-specific IgE binds to membrane receptors on tissue mast cells and blood basophils and then releases a series of chemicals (histamine, leukotrienes, cytokines and proteases) that regulate the allergic reaction. While the allergic reaction begins immediately, signs and symptoms of the reaction may occur within seconds or minutes (immediate hypersensitivity), may be delayed for several hours (delayed hypersensitivity), or may involve both early- and late-phase reactions.

Allergy tests are performed to verify or exclude the presence of IgE-mediated hypersensitivity and to identify the causative allergen(s). Testing may involve in vivo procedures, which determine the presence of specific IgE by administering an IgE-specific allergen into, on or near the patient and monitoring the patient's physiological response(s). Allergy tests may also be in vitro procedures that determine the presence of specific IgE or elevated total IgE by analyzing patient serum.

The allergy testing methods and recommendations detailed below are based primarily on practice parameters and recommendations from the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American Academy of Otolaryngic Allergy (AAOA).

### **In Vivo Allergy Testing**

In vivo allergy tests fall into two general categories: skin tests and organ challenge (or provocation) tests. Both are designed to confirm hypersensitivity and identify the antigen(s) responsible for the allergic reaction. The most common in vivo allergy tests are outlined below. The efficacy of some in vivo allergy tests has not been firmly established, due to the limited numbers of well-designed clinical trials. Few prospective studies are available, and evidence is primarily in the form of expert opinion.

Skin testing can be utilized to detect immediate hypersensitivity (IgE-dependent reactions) and delayed hypersensitivity (cell-mediated immune reactions). The two major methods of skin testing for IgE-mediated disease include the prick-puncture test and the intradermal test. A positive response to skin testing is typically indicated by the presence of a wheal and/or flare at the test site. Scratch testing is no longer a recommended allergy testing procedure, due to reproducibility issues and the high incidence of false-positive reactions.

Skin testing is contraindicated in patients with severe dermatographism (allergy in which a pale, raised wheal is produced when skin is scratched), ichthyosis (condition in which skin is dry and scaly, resembling fish skin) or generalized eczema; in patients who cannot be withdrawn from medications that interfere with skin testing (such as long-acting antihistamines and tricyclic antidepressants); and in patients who have a history of a previous systemic reaction to skin testing.

Prick/puncture tests are used for confirmation of clinical immediate hypersensitivity induced by inhalant and food allergens. Skin prick/puncture tests are generally considered the most specific screening method for detecting the presence of IgE antibodies in patients with appropriate exposure histories. These tests may also be used in the diagnosis of drug and chemical hypersensitivity reactions. Prick/puncture tests are generally less sensitive than intradermal testing. For inhalant allergies, prick/puncture tests have been shown to correlate better with the presence of clinical allergy. Skin testing is considered the gold standard for the diagnosis of IgE-mediated allergic disease. The Joint Task Force of Allergy, Asthma, and Immunology recommends skin prick/puncture tests as the primary test for the diagnosis of IgE-mediated allergic diseases.

Intradermal or intracutaneous tests are generally used when increased sensitivity is the main goal of testing (i.e., when prick/puncture tests are negative despite a compatible history of exposure). Intradermal tests are more sensitive but less specific than prick/puncture tests for most allergens but are superior to other skin tests for assessing hypersensitivity to hymenoptera (stinging insects) and penicillin or allergens of lower potency.

Repeat skin testing with multiple antigens is not indicated on a regular basis (e.g., yearly). Indications for repeat testing include changing symptoms, new exposures, or 3–5 years of venom immunotherapy.

Patch testing is used to determine the presence or cause of delayed hypersensitivity reactions originating on the skin. It is primarily used to assess allergic contact dermatitis, an eczema-type, immunologically-mediated skin reaction which is largely cell-mediated but may contain an IgE-mediated component. The clinical utility of patch testing to identify allergic reactions other than those originating on the skin (such as inhalants or food allergens)

has not been determined. It is estimated that 20–30 antigens used in the panel of patch tests will identify between 50% and 70% of the clinically relevant causes of contact dermatitis.

Certain substances may elicit an allergic reaction only when exposed to light. In photo patch testing, the suspected chemical or medication is applied in two separate areas. One of the areas is exposed to a range of ultraviolet type A light and then examined for the presence of a reaction. Testing is considered positive if only the area that has been exposed to the ultraviolet light demonstrates an allergic reaction.

Oral challenge may be used to confirm or diagnose IgE-mediated hypersensitivity to specific foods, food additives and preservatives, or drugs. Food challenge is time-consuming and associated with the potential for anaphylaxis. Simpler measures, such as skin tests and elimination of suspected foods from the diet, are typically tried first. If skin tests are negative or equivocal and inconsistent with a history suggestive of food allergy, and symptoms abate after elimination of suspected foods, one food at a time is added back into the diet (open food challenge) until symptoms recur. Blinded, controlled food challenge (by ingestion) may be undertaken when skin tests are negative or inconsistent with a history that suggests food allergy. Sublingual food allergy testing, in which the food in question is placed under the tongue and not ingested, is an unproven testing method (see "provocation-neutralization," below). Double-blind food challenges are typically reserved for a select subset of patients.

Drug provocation/ bronchial challenge testing is typically undertaken only if the need to confirm or exclude hypersensitivity outweighs the risk of severe reaction. This may occur in patients who have a history of allergy to a particular drug for which there is no effective alternative but who need that drug for treatment. Bronchial challenge testing is used in the diagnosis and management of asthma to quantify allergic airway responsiveness to pharmacological agents, such as methacholine or histamine. Bronchial provocation/challenge testing with extracts of common aeroallergens such as dust or ragweed, however, has no established clinical value and offers no additional clinical information beyond that obtained by a well-taken clinical history and a carefully performed skin test.

Serial endpoint titration (SET) is a variation of intradermal skin testing in which increasing doses of antigen are used to determine the concentration at which the reaction changes from negative to positive (i.e., the endpoint). SET has been used as an alternative to skin prick testing or in vitro testing and has also been used to guide initiation of immunotherapy, with the endpoint dilution used as the starting dose. Although not considered a replacement for skin testing, SET may be indicated for determination of a safe starting dose for testing or immunotherapy when there is potential for the specific allergen in question to produce a severe systemic reaction or anaphylaxis (such as with bee venom).

#### **Additional In Vivo Diagnostic Procedures**

Nasal challenge/provocation testing has been proposed as a tool in the diagnosis of allergic rhinitis. It is used in studies of allergic rhinitis, but its utility in clinical practice has not been established. Evidence available regarding the value of this testing is primarily in the form of expert opinion rather than studies assessing the technique. A review of the current published, peer-reviewed scientific literature indicates that the role of nasal challenge testing in the diagnosis and management of allergic diseases has not been established.

Conjunctival challenge testing also has been used in the diagnosis of allergic rhinitis as well as of allergic conjunctivitis. Few data are available regarding the value of conjunctival challenge. The role of conjunctival challenge testing in the diagnosis and management of allergic diseases has not been established, based on a review of the published, peer-reviewed scientific literature.

Provocation-neutralization, sometimes referred to as the Rinkel test, is a procedure that evolved from serial endpoint titration. This method has been proposed as a test for allergies to foods, inhalants and environmental chemicals; it exposes the patient to test doses of substances intradermally, subcutaneously or sublingually, with the goal of either producing or preventing symptoms. There are no standardized protocols, and its safety and efficacy have not been established. Both the American College of Physicians and the American Academy of Allergy and Immunology consider this testing method unproven. Provocation-neutralization is a method often used by physicians who subscribe to the concept of multiple food and chemical sensitivities, also referred to as idiopathic environmental intolerances (IEIs). Based on a review of the current published, peer-reviewed scientific literature, provocation-neutralization is an unproven testing method.

Electrodermal testing, also referred to as "electro-acupuncture," has been proposed as a method to identify substances, especially foods, to which the patient is allergic and to provide information about optimal dilution of treatment extracts in immunotherapy. It is performed with a device that uses a galvanometer to measure electrical activity of the skin at designated acupuncture points. There is no scientific or clinical evidence available that demonstrates that electrodermal testing can diagnose allergies. This technique is considered unproven.

Applied kinesiology involves testing for specific allergies by measuring the patient's muscle strength. Allergens are placed in containers that the patient holds in one hand while a technician estimates muscle strength in the opposite arm. Based on a review of the published, peer-reviewed scientific literature, this technique is unproven.

Reaginic pulse testing involves measuring a change in pulse rate after the ingestion, injection or sublingual application of an allergen. There is no basis for its role in the diagnosis of allergic disease. A review of the literature indicates that this is an unproven test for the diagnosis of allergies.

### **In Vitro Allergy Testing**

The discovery of the role of IgE in clinical allergy testing resulted in the development of in vitro diagnostic assays to test for allergen sensitivity. The first immunoassays were developed to quantify the serum concentration of total IgE. In normal individuals, IgE is usually present at low levels; 130 ng/ml represents the upper limit of the normal range. However, a significant number of asymptomatic normal individuals, such as those with parasitic diseases or with depressed cell-mediated immunity, exceed this level. Also, some allergic patients may exhibit normal total IgE levels in the presence of elevated levels of specific IgE. Methods were therefore developed to assay allergen-specific IgE. The radioallergosorbent test (RAST) system was developed for in vitro measurement of specific IgE in a patient's serum. Other in vitro tests for specific IgE have been developed and employ the same principles as the RAST but use an enzymatic (MAST) or fluorogenic (FAST) detection system in place of a radioactive label.

In vitro tests that screen for multiple allergens in a single assay (Phadiatop<sup>®</sup>, Pharmacia Diagnostics) or that can be used in an automated system (ImmunoCAP<sup>®</sup>, Pharmacia Diagnostics) have been developed. The ImmunoCAP is designed as a "sandwich" immunoassay. The sensitivity and specificity of the ImmunoCAP compares favorably with those of the modified PhadezymRAST<sup>®</sup> system. Results from studies have indicated that, when compared to skin prick testing as the gold standard, the ImmunoCAP system has been shown to have a greater sensitivity (80–95%) than RAST and to have similar specificity (85%). Other modified versions of the RAST test include the PRIST, RIST, MRT (modified RAST) and ELISA IgE tests.

The overall sensitivity of in vitro immunoassays compared with prick/puncture skin tests has been reported to range from 50–90%, with an average of about 70–75% from most studies. Skin testing, therefore, continues to be the preferred method for the diagnosis of IgE-mediated sensitivity. Selective use of in vitro tests may be justified for patients in whom skin testing is inappropriate. Situations in which specific IgE immunoassays may be appropriate include:

- testing of patients with severe dermatographism, ichthyosis or generalized eczema
- testing in patients who cannot be withdrawn from medications that interfere with skin testing (patients receiving long-acting antihistamines or tricyclic antidepressants)
- testing in patients who have a clinical history suggesting an unusually greater risk for anaphylaxis or who have had a previous systemic reaction to skin testing
- testing of patients with mental or physical impairments

It should be noted that specific IgE immunoassays do not have sufficient sensitivity for absolute positive prediction of anaphylactic sensitization to venoms, penicillin and other drugs. This method of testing should not be used to provide definitive diagnoses, due to the potential for serious consequences resulting from a false-negative outcome. Allergen-specific IgE immunoassays provide neither diagnostic nor prognostic information when measured in the cord blood of newborn infants.

In vitro allergy testing is not indicated when there are no contraindications to skin testing or in patients who are successfully being treated for allergies, have mild symptoms and a short allergy season, or have had negative skin testing for the allergy in question.

Total serum IgE testing in patients with allergic disease has no established clinical role. Substantial proportions of individuals with IgE-mediated allergic disease have normal serum IgE levels, and many nonallergic diseases are associated with elevated serum IgE. Measurement of serum IgE may be indicated in adults with conditions such as suspected allergic bronchopulmonary aspergillosis and hyper-IgE syndromes (dermatitis and recurrent pyogenic infections), certain stages of HIV infection, IgE myeloma, drug-induced interstitial nephritis, graft-versus-host disease, several parasitic diseases and specific immune deficiency diseases. In children, serum concentrations of IgE increase slowly with development, with highest levels typically found in late adolescence. High concentrations of serum IgE measured in the first year of life have been shown to correlate with future development of atopic disease. However, in clinical situations when presenting signs of allergic disease are evident, total IgE levels do not provide additional diagnostic information. Furthermore, normal IgE levels do not exclude the diagnosis of allergic disease in infants or children.

Total serum IgG, IgA and IgM testing is not typically clinically useful, since their levels are not altered by allergic diseases. Based on a review of the literature, the role of routine quantitative measurement of serum IgG, IgA and IgM in the diagnosis and management of allergic disease has not been established.

Serum IgG antibodies are not involved in the pathogenesis of atopic disease. Although it has been suggested that IgG antibodies may be responsible for delayed symptoms or vague intolerance to foods, there is no evidence available that validates this contention. RAST and similar technologies are capable of detecting minute quantities of such antibodies, and it is known that low-level IgG antibodies to foods circulate normally but have no known pathogenic significance. The measurement of specific IgG antibodies is of no diagnostic value in the management of patients with atopic (allergic) disease. There is insufficient evidence in the published, peer-reviewed scientific literature to support the use of specific IgG antibody testing by RAST or ELISA in the diagnosis or treatment of allergic disease without suspected immunodeficiency.

The cytotoxic test, also known as the "leukocytotoxic test" or Bryan's Test, has been proposed for food allergies but has no scientific support as a procedure for the diagnosis of food allergies or inhalant allergies. The rationale for this test is based on a claim that morphological changes in peripheral-blood leukocytes in contact with allergens in vitro indicate that the patient is allergic to the particular allergen. There is insufficient evidence in the published, peer-reviewed scientific literature to support the use of this testing in the diagnosis or management of allergic disease. The role of this testing in the diagnosis or management of allergic disease has not been established.

Lymphocyte subset counts may be useful in the diagnosis of lymphocyte cellular immunodeficiencies and lymphocytic leukemias. Quantifying lymphocyte subsets, however, has not been proven to be of any value in the diagnosis or management of allergic disease.

Lymphocyte function assays may be appropriate in the diagnosis of some immunodeficiency diseases; however, they are not abnormal in allergic diseases. The use of this testing in the diagnosis or management of allergic disease is unproven.

Cytokine and cytokine receptor assays have not been shown to be useful in the diagnosis or management of any allergic disease and are therefore considered unproven.

The food immune complex assay (FICA) is based on the solid-phase radioimmunoassay methodology. It has not been shown in well-designed clinical trials that any well-defined clinical disease involves pathogenic circulating immune complexes to foods. Furthermore, it has not been shown that the assay for such complexes is diagnostic of any disease. The clinical value of food immune complex assays in the diagnosis and management of allergic disease has not been established. The technique is therefore considered unproven.

Leukocyte histamine release testing is an in vitro test that evaluates the presence of specific IgE antibodies. The test has been proposed for the diagnosis of various allergic conditions, including atopic disorders and stinging insect allergies. Leukocyte histamine release testing detects the release of histamine from basophils in a sample of whole blood exposed to allergens in vitro. It is a cumbersome test typically conducted in research laboratories, and has not been studied fully for its predictive value in determining specificity and sensitivity. Its role in the diagnosis and management of allergic disease outside of the investigative setting has not been established.

Body chemical analysis is typically seen in the diagnosis of a condition known as "idiopathic environmental intolerances" (IEIs) or "multiple food and chemical sensitivities." Samples of whole blood, serum, erythrocytes, urine, fat and hair are tested for the presence of environmental chemicals. The most common chemicals measured are organic solvents, other hydrocarbons, pesticides and metals. Some proponents of this testing also recommend measurements of the quantity of vitamins, minerals and amino acids in blood and urine in a search for "environmental sensitivities." The concept of multiple food and chemical sensitivities manifested by numerous symptoms in the absence of objective physical findings lacks scientific foundation. There is no evidence to suggest that these patients suffer from an immunological abnormality. The existence of such an illness is based on anecdotal reports with no verification using well-designed clinical trials. There is no scientific evidence to support the value of diagnostic testing associated with IEIs or multiple food and chemical sensitivities, including body chemical analysis. Body chemical analysis is therefore considered unproven.

Antigen leukocyte cellular antibody testing (ALCAT) is an automated method of testing for food allergies that is purported to identify food sensitivity by using a modified Coulter counter linked to a computer program to measure the change in white blood cells incubated with purified food and mold extract. There is insufficient evidence in the published peer-reviewed scientific literature to support the use of this testing in the diagnosis or management of allergic disease.

### Summary

In vivo allergy testing (i.e., skin test, organ challenge/provocation test) is the most commonly used and preferred method of allergy testing. In vivo allergy tests are designed to confirm hypersensitivity and identify the antigen(s) responsible for the allergic reaction. In vitro allergy testing has been demonstrated to be an effective alternative for patients with suspected IgE-mediated food or inhalant allergies who cannot be tested using in vivo methods, or as an alternative to skin testing for the evaluation of cross-reactivity between insect venoms. In addition, specific IgE immunoassays may be used as adjunctive testing for disease activity of allergic bronchopulmonary aspergillosis and certain parasitic diseases.

## Coding/Billing Information

**Note:** This list of codes may not be all-inclusive.

**Covered when medically necessary:**

CPT®* Codes	Description
86001	Allergen specific IgG quantitative or semiquantitative, each allergen
86003	Allergen specific IgE; quantitative or semiquantitative, each allergen
86005	Allergen specific IgE; qualitative, multiallergen screen (dipstick, paddle or disk)
95004	Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report by a physician, specify number of tests
95010	Percutaneous tests (scratch, puncture, prick) sequential and incremental, with drugs, biologicals or venoms, immediate type reaction, specify number of tests
95015	Intracutaneous (intra-dermal) tests, sequential and incremental, with drugs, biologicals, or venoms, immediate type reaction, specify number of tests
95024	Intracutaneous (intra-dermal) tests with allergenic extracts, immediate type reaction, including test interpretation and report by a physician, specify number of tests
95027	Intracutaneous (intra-dermal) tests, sequential and incremental, with allergenic extracts for airborne allergens, immediate type reaction, including test interpretation and report by a physician, specify number of tests
95028	Intracutaneous (intra-dermal) tests with allergenic extracts, delayed type reaction, including reading, specify number of tests
95044	Patch or application test(s) (specify number of tests)
95052	Photo patch test(s) (specify number of tests)

95070	Inhalation bronchial challenge testing (not including necessary pulmonary function tests); with histamine, methacholine, or similar compounds
95071	Inhalation bronchial challenge testing (not including necessary pulmonary function tests); with antigens or gases, specify
95075	Ingestion challenge test (sequential and incremental ingestion of test items, eg, food, drug or other substance such as metabisulfite)

ICD-9-CM Diagnosis Codes	Description
477.0-477.9	Allergic rhinitis
493.00-493.02	Extrinsic asthma
493.90-493.92	Asthma, unspecified
518.6	Allergic bronchopulmonary aspergillosis
530.13	Eosinophilic esophagitis
558.3	Allergic gastroenteritis and colitis
692.0-692.9	Contact dermatitis and other eczema
693.0-693.9	Dermatitis due to substances taken internally
708.0	Allergic urticaria
708.3	Dermatographic urticaria
708.9	Urticaria, unspecified
757.1	Ichthyosis congenita
786.07	Wheezing
786.2	Cough
989.5	Toxic effect of other substances, venom
995.0	Other anaphylactic shock not else where classified
995.2	Unspecified adverse effect of drug medicinal and biological substance, not elsewhere classified
995.3	Allergy, unspecified not elsewhere classified
995.60-995.69	Anaphylactic shock due to adverse food reaction
995.7	Other adverse food reactions, not elsewhere classified
V72.7	Diagnostic skin and sensitization tests

**Experimental/Investigational/Unproven/Not Covered:**

CPT* Codes	Description
82784	Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each
86343	Leukocyte histamine release test (LHR)
95060 <sup>†</sup>	Ophthalmic mucous membrane tests
95065	Direct nasal mucous membrane test
95199 <sup>††</sup>	Unlisted allergy/clinical immunologic service or procedure

<sup>†</sup>**NOTE:** Experimental, investigational, unproven and not covered when used to report ophthalmic mucous membrane testing for the management of allergic disease.

<sup>††</sup>**NOTE:** Experimental, investigational, unproven and not covered when used to report any procedure listed as such in this Coverage Policy.

\*Current Procedural Terminology (CPT®) © 2010 American Medical Association: Chicago, IL.

## References

1. Alonso R, Botey J, Pena JM, Eseverri JL, Marin A, Ras RM. Specific IgE determination using the CAP system: comparative evaluation with RAST. *J Investig Allergol Clin Immunol*. 1995 May-Jun;5(3):56-60.
2. American Academy of Allergy, Asthma and Immunology (AAAAI). Allergen skin testing [position statement]. *J Allergy Clin Immunol*. 1993;(92):636-7.
3. American Academy of Allergy, Asthma and Immunology (AAAAI). Work group report: allergy diagnosis in clinical practice. Nov 2006. Accessed Apr 8, 2011. Available at URL address: [http://www.aaaai.org/media/resources/academy\\_statements/](http://www.aaaai.org/media/resources/academy_statements/)
4. American Academy of Allergy, Asthma and Immunology (AAAAI). The use of in vitro tests for IgE antibody in the specific diagnosis of IgE-mediated disorders and in the formulation of allergen immunotherapy [position statement]. *J Allergy Clin Immunol*. 1992;(90):263-7.
5. American Academy of Otolaryngology—Head and Neck Surgery. Clinical indicators-allergy testing for allergic rhinitis. Accessed Apr 8, 2011 Available at URL address: [http://www.entnet.org/practice/products/indicators/allergy\\_testing.html](http://www.entnet.org/practice/products/indicators/allergy_testing.html)
6. Bernstein IL, Storms WW. Practice parameters for allergy diagnostic testing. Joint Task Force on Practice Parameters for the Diagnosis and Treatment of Asthma. The American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. *Ann Allergy Asthma Immunol*. 1995 Dec;75(6 Pt 2):543-625.
7. Brooks GD, Bush RK. Allergens and other factors important to atopic disease. In: Grammer LC, Greenberger PA, editors. *Patterson's allergic diseases*, 7th ed. Lippincott, Williams & Wilkins; 2009.
8. Corey JP, Mamikoglu B, Akbar I, Houser SM, Gungor A. ImmunoCAP and HyTEC enzyme immunoassays in the detection of allergen-specific IgE compared with serial skin end-point titration by receiver operating characteristic analysis. *Otolaryngol Head Neck Surg*. 2000 Jan;122(1):64-70.
9. Darsow U, Vieluf D, Ring J. Evaluating the relevance of aeroallergen sensitization in atopic eczema with the atopy patch test: a randomized, double-blind multicenter study. *J Am Acad Dermatol*. 1999 Feb;40(2 Pt 1):87-93.
10. Dente FL, Bacci E, di Franco A, Giannini D, Conti I, Macchioni P. Reproducibility of early and late asthmatic responses to allergen challenge in a large group of asthmatics. *Respir Med*. 2000 May;94(5):41-7.
11. Emanuel IA. In vitro testing for allergy diagnosis: comparison of methods in common use. *Otolaryngol Clin North Am*. 1998 Feb;31(1):27-34.
12. Fox RA, Sabo BM, Williams TP, Joffres MR. Intradermal testing for food and chemical sensitivities: a double-blind controlled study. *J Allergy Clin Immunol*. 1999 May;103(5 Pt 1):907-11.
13. Gleeson M, Cripps AW, Hensley MJ, Wlodarczyk JH, Henry RL, Clancy RL. A clinical evaluation in children of the Pharmacia ImmunoCAP system for inhalant allergies. *Clin Exp Allergy*. 1996 Jun;26(6):697-702.
14. Gordon BR. Allergy skin tests for inhalants and foods: comparison of methods in common use. *Otolaryngol Clin North Am*. 1998 Feb;31(1):35-53.
15. Hill DJ, Hosking CS, Reyes-Benito LV. Reducing the need for food allergen challenges in young children: a comparison of in vitro with in vivo tests. *Clin Exp Allergy*. 2001 Jul;31(7):1031-5.

16. Lewith GT, Kenyon JN, Broomfield J, Prescott P, Goddard J, Holgate ST. Is electrodermal testing as effective as skin prick tests for diagnosing allergies? a double-blind, randomised block design study. *BMJ*. 2001 Jan 20;322(7279):131-4.
17. Li JT, Lockey RF, Bernstein IL, Portnoy JM, Nicklas RA, editors; Joint Task Force on Practice Parameters. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology (AAAAI) and American College of Allergy, Asthma and Immunology (ACAAI). *Ann Allergy Asthma Immunol*. 2003 Jan;(90)(Suppl 1):1-40.
18. Li JT, Pearlman DS, Nicklas RA, Lowenthal M, Rosenthal RR, et al. Algorithm for the diagnosis and management of asthma: a practice parameter update: Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. *Ann Allergy Asthma Immunol*. 1998 Nov;81(5 Pt 1):415-20.
19. Lytvyakova LI, Baraniuk JN. Nasal provocation testing: a review. *Ann Allergy Asthma Immunol*. 2001 Apr;86(4):355-64.
20. Majamaa M, Moisiö P, Holm K, Turjanmaa K. Wheat allergy: diagnostic accuracy of skin prick and patch tests and specific IgE. *Allergy*. 1999 Aug;54(8):851-6.
21. Middleton E, Ellis EF, Yunginger JW, Reed CE, Adkinson NF, Busse WW, editors. *Allergy principles and practices: vols. I and II*. 5<sup>th</sup> ed. St. Louis, MO: Mosby; 1998. Chapters 32-34, 83, 86, 88.
22. National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI). National Asthma Education and Prevention Program expert panel report 3: guidelines for the diagnosis and management of asthma. 2007 Jul. Accessed Apr 12, 2010. Available at URL address: <http://www.nhlbi.nih.gov/guidelines/index.htm>
23. Niggemann B, Reibel S, Roehr CC, Felger D, Ziegert M, Sommerfeld C. Predictors of positive food challenge outcome in non-IgE-mediated reactions to food in children with atopic dermatitis. *J Allergy Clin Immunol*. 2001 Dec;108(6):1053-8.
24. Niggemann B, Reibel S, Wahn U. The atopy patch test (APT): a useful tool for the diagnosis of food allergy in children with atopic dermatitis. *Allergy*. 2000 Mar;55(3):281-5.
25. Ortolani C, Ballmer-Weber BK, Hansen KS, Ispano M, Wuthrich B, Bindslev-Jensen C, et al. Hazelnut allergy: A double-blind, placebo-controlled food challenge multicenter study. *J Allergy Clin Immunol*. 2000 Mar;105(3):577-81.
26. Reisman RE. Allergy to stinging insects. In: Grammer LC, Greenberger PA, editors. *Patterson's allergic diseases*, 7th ed. Lippincott, Williams & Wilkins; 2009.
27. Salzano FA. Specific nasal provocation test with powder allergen. *Allergy*. 1997;52:32-5.
28. Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. *J Allergy Clin Immunol*. 2001 May;107(5):891-6.
29. Schafer T, Hoelscher B, Adam H, Ring J, Wichman HE, Heinrich J. Hay fever and predictive value of prick test and specific IgE antibodies: A prospective study in children. *Pediatr Allergy Immunol*. 2003 Apr;14(2):120-9.
30. Sicherer SH, Morrow EH, Sampson HA. Dose-response in double-blind, placebo-controlled oral food challenges in children with atopic dermatitis. *J Allergy Clin Immunol*. 2000 Mar;105(3):582-6.
31. Terr AI. Controversial and unproved methods in allergy diagnosis and treatment. In: Grammer LC, Greenberger PA, editors. *Patterson's allergic diseases*, 7th ed. Lippincott, Williams & Wilkins; 2009.

32. U.S. Food and Drug Administration (FDA). Radioallergosorbent test (RAST) methods for allergen-specific immunoglobulin E (IgE) 510(k)s: final guidance for industry and FDA. 2001 Aug 22. Accessed Apr 9, 2009. Available at URL address: <http://www.fda.gov/cdrh/ode/guidance/800.html>
33. Williams PB, Barnes JH, Szeinbach SL, Sullivan TJ. Analytic precision and accuracy of commercial immunoassays for specific IgE: establishing a standard. *J Allergy Clin Immunol.* 2000 Jun;105(6 Pt 1):1221-30.
34. Williams PB, Siegel C, Portnoy J. Efficacy of a single diagnostic test for sensitization to common inhalant allergens. *Ann Allergy Asthma Immunol.* 2001 Feb;86(2):196-202.
35. Witteman AM, Stapel SO, Perdok GJ. The relationship between RAST and skin test results in patients with asthma or rhinitis: a quantitative study with purified major allergens. *J Allergy Clin Immunol.* 1996;97:16-25.
36. Wojnarowski C, Storm Van's Gravesande K, Riedler J, Eichler I, Gartner C, Frischer T. Comparison of bronchial challenge with ultrasonic nebulized distilled water and hypertonic saline in children with mild-to-moderate asthma. *Eur Respir J.* 1996;9:1896-901.

## Policy History

<b>Pre-Merger Organizations</b>	<b>Last Review Date</b>	<b>Policy Number</b>	<b>Title</b>
CIGNA HealthCare	05/15/2008	0070	Allergy Testing

“CIGNA”, “CIGNA HealthCare” and the “Tree of Life” logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Health and Life Insurance Company, CIGNA Behavioral Health, Inc., CIGNA Health Management, Inc., and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company or CIGNA Health and Life Insurance Company.